Purpose: 3 For Life aims to increase hepatitis B virus (HBV) awareness and reduce the high prevalence of undiagnosed chronic HBV infection and susceptibility among Asian/Pacific Islander (API) adults.
Design: This pilot program offered low-cost HBV vaccination with free HBV testing targeted primarily at foreign-born Chinese adults.
Setting: Semimonthly screening and vaccination clinics were held in San Francisco, California, for 1 year.
Subjects: A total of 1206 adults accessed the program.
Intervention: Participants paid a discounted fee for a full vaccine series against HBV, hepatitis A virus (HAV), or both. Participants also provided blood samples for HBV serologic testing. Test results, recommendations, and appointment reminders were provided by mail.
Measures: We compared the probability of completing a recommended vaccine series by HBV serologic status and sociodemographic characteristics.
Analysis: Proportions were compared using multivariate logistic regression models.
Results: Nine percent of adults were chronically infected with HBV, and 53% were unprotected. In the latter group, 85% completed the HBV vaccine series. The probability of completing a recommended hepatitis vaccine series was similar across most sociodemographic groups, with slightly higher completion rates among middle-aged and Chinese participants.
Conclusions: Lessons learned from this pilot program have been used toward successful replication in other cities, demonstrating that 3 For Life is an accessible, affordable, reproducible, and sustainable model to increase HBV awareness, testing, and prevention among API adults.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4278/ajhp.071025115 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Complement inhibition in seropositive generalized myasthenia gravis as rescue therapy in impending and effective treatment in frequently recurring impending myasthenic crisis-a case series.
Ther Adv Neurol Disord
December 2024
Department of Neurology, Faculty of Medicine, University of Augsburg, Stenglinstrasse 2, Augsburg 86156, Germany.
In seropositive myasthenia gravis (MG), complement inhibition has been shown to be an effective and a fast-acting therapeutic option. Myasthenic crisis (MC), usually preceded by impending MC, is a life-threatening complication requiring highly effective treatments with rapid onset of action. Currently used treatment options of MC are limited, consisting mainly of symptomatic and immune therapies, that is, intravenous immunoglobulins and plasma exchange/immunoadsorption.
View Article and Find Full Text PDFCase Series of Vaccine Hesitancy Encountered at the Pediatric Emergency Department.
Cureus
November 2024
Department of Pediatrics, Hamamatsu University School of Medicine, Hamamatsu-shi, JPN.
Vaccine hesitancy (VH) is a significant concern, although its specific characteristics remain unclear. Moreover, strategies to shift vaccine-hesitant parents' attitudes toward immunization are not yet well-defined. Pediatric emergency department (ED) physicians frequently encounter patients who are inadequately vaccinated due to parental VH; however, it is challenging to allocate sufficient time during ED visits to provide comprehensive vaccination education.
View Article and Find Full Text PDFCOVID-19 vaccine effectiveness against SARS-CoV-2-confirmed hospitalisation in the eastern part of the WHO European Region (2022-2023): a test-negative case-control study from the EuroSAVE network.
Lancet Reg Health Eur
December 2024
World Health Organization Regional Office for Europe, Denmark.
Background: Understanding COVID-19 vaccine effectiveness (VE) in preventing severe disease is critical to inform vaccine policy. We used the test-negative design to estimate VE against SARS-CoV-2-confirmed hospitalisation in adults ≥18 years in the eastern WHO European Region.
Methods: We included patients hospitalised for severe acute respiratory infection (SARI) at sentinel surveillance sites in Albania, Georgia, Kyrgyzstan, North Macedonia, Serbia, and in Kosovo.
The Impact of Public Health and Social Measures (PHSMs) on SARS-CoV-2 Transmission in the WHO European Region (2020-2022).
Influenza Other Respir Viruses
December 2024
Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK.
Background: Between 2020 and 2022, countries used a range of different public health and social measures (PHSMs) to reduce the transmission of SARS-CoV-2. The impact of these PHSMs varied as the pandemic progressed, variants of concern (VOCs) emerged, vaccines rolled out and acceptance/uptake rates evolved. In this study, we assessed the impact of PHSMs in the World Health Organization (WHO) European Region during VOC phases.
View Article and Find Full Text PDFOncological outcomes and prognostic implications of T1 histo-anatomic substaging in the management of high-Grade non-muscle invasive bladder cancer: results from a large single centre series.
World J Urol
December 2024
Department of Urology and Organ Transplantation, University of Foggia, Foggia, Italy.
Purpose: This study aimed to comprehensively evaluate the prognostic value of T1 histo-anatomic substaging (T1a/T1b) for high grade (HG) non-muscle invasive bladder cancer (NMIBC) over a large single-centre cohort.
Materials And Methods: Patients with primary HG T1 NMIBC were identified from our Institutional database, between 2011 and 2022. Data from diagnosis to repeated transurethral resection of bladder tumour (RE-TURBT), bacillus Calmette-Guérin (BCG) treatment and follow-up were collected.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!